{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:43:38Z","timestamp":1781891018834,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.jinf.2005.01.005","type":"journal-article","created":{"date-parts":[[2005,2,3]],"date-time":"2005-02-03T07:16:49Z","timestamp":1107415009000},"page":"211-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Clinical implications of extended spectrum \u03b2-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness"],"prefix":"10.1016","volume":"51","author":[{"given":"Srividya","family":"Kotapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2005.01.005_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0732-8893(98)00037-6","article-title":"Bacterial resistance: a worldwide problem","volume":"31","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2005.01.005_bib2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/319757","article-title":"Extended spectrum \u03b2-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact on outcomes","volume":"32","author":"Lautenbach","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2005.01.005_bib3","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microb"},{"key":"10.1016\/j.jinf.2005.01.005_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1086\/324742","article-title":"Molecular correlation for the treatment outcomes in blood stream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime","volume":"34","author":"Wong-Beringer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2005.01.005_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum \u03b2-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2005.01.005_bib6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/322667","article-title":"Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum \u03b2 lactamase producing Escherichia coli and Klebsiella pneumoniae","volume":"33","author":"Lautenbach","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2005.01.005_bib7","article-title":"Clinical outcomes of cefepime treatment on infections caused by ESBL and Amp C producing Enterobacteriaceae [abstract # 1716]","author":"Joshi","year":"2000"},{"key":"10.1016\/j.jinf.2005.01.005_bib8","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem\u2013cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2005.01.005_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.diagmicrobio.2003.11.009","article-title":"Prevalence of extended spectrum \u03b2-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut","volume":"49","author":"Dandekar","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2005.01.005_bib10","unstructured":"NCCLS. Performance standards for antimicrobial susceptibility testing. Fourteenth Informational Supplement. NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898 USA; 2004."},{"key":"10.1016\/j.jinf.2005.01.005_bib11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","article-title":"Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin\u2013tazobactam program in a large community teaching hospital","volume":"22","author":"Grant","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jinf.2005.01.005_bib12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2005.01.005_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1592\/phco.21.6.583.34537","article-title":"Therapeutic challenges associated with extended spectrum, \u03b2-lactamase producing Escherichia coli and Klebsiella pneumoniae","volume":"21","author":"Wong-Beringer","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jinf.2005.01.005_bib14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1592\/phco.23.12.1232.32706","article-title":"Clinical and microbiologic analysis of a hospital's extended-spectrum \u03b2-lactamase-producing isolates over a 2-year period","volume":"23","author":"Burgess","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jinf.2005.01.005_bib15","first-page":"817","article-title":"Authors reply: retrospective study of clinical outcomes with extended-spectrum \u03b2-lactamases\u2014a different interpretation","volume":"24","author":"Burgess","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jinf.2005.01.005_bib16","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.48.6.1941-1947.2004","article-title":"Determination of the in vivo pharmacodynamic profile of cefepime against extended spectrum \u03b2-lactamase producing Escherichia coli at various inocula","volume":"48","author":"Maglio","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2005.01.005_bib17","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin\u2013tazobactam, and the inoculum effect in tests with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thompson","year":"2001","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445305000150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445305000150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:28:26Z","timestamp":1758986906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445305000150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0163445305000150"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2005.01.005","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of extended spectrum \u03b2-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2005.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}